RNA

Atrium TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$20.00

+63.3% vs current

Most likely

Base case

45%

Probability

Target price

$12.00

-2.0% vs current

B-

Bear case

30%

Probability

Target price

$7.00

-42.9% vs current

AI sentiment snapshot

Latest data as of 2026-05-07

AI commentary

Primary-source flow is better than the external coverage: the February separation/launch filings and materials established ownership, cash, and program timing, while the April 23 BMS milestone added one fresh positive datapoint [#8-K-2026-02-27] [#PR-2026-04-23]. Still, coverage remains thin, peers are loose, there is no earnings readout, and the deterministic packet points to neutral direction with very high uncertainty and weak evidence quality, so this remains a monitoring-style setup rather than a high-conviction thesis.

RankAlpha Sentiment Codex - 2026-05-07

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-23catalyst$15 million Bristol Myers Squibb milestone supports platform validation and cash bufferMedium impact

On April 23, 2026 Atrium said it earned a $15 million development milestone from Bristol Myers Squibb after successful delivery of a development candidate under the cardiovascular collaboration [#PR-2026-04-23]. The payment is positive but does not replace the need for lead-program clinical execution.

2026-12-31catalystATR 1086 moves the second cardiomyopathy asset toward IND-enabling executionHigh impact

Atrium's February 2026 presentation says ATR 1086 for PLN cardiomyopathy has preclinical proof-of-concept, with IND-enabling studies planned to initiate in 2026 and an IND filing anticipated in 2027 [#IR-2026-02]. A second program advancing on schedule would strengthen the platform narrative, but visibility is still early-stage.

2027-05-07catalystATR 1072 IND filing and Phase 1 start remain the key de-risking stepHigh impact

Atrium's February 2026 investor presentation says ATR 1072 for PRKAG2 syndrome has completed preclinical proof-of-concept and successful pre-IND work, with IND filing planned in 2H 2026 and Phase 1 initiation subject to clearance [#IR-2026-02]. This is the clearest forward catalyst for a company that is still preclinical despite the February spin-off and launch [#8-K-2026-02-27] [#PR-2026-02-27].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-07 • Updated nightlySource: Internal modelMethodology